Research programme: monoclonal antibodies pain therapeutics - Integral Molecular
Latest Information Update: 04 Nov 2022
At a glance
- Originator Integral Molecular
- Class Analgesics; Monoclonal antibodies
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Pain
Most Recent Events
- 19 Oct 2022 Research programme: monoclonal antibodies pain therapeutics - Integral Molecular is available for licensing as of 19 Oct 2022. https://www.integralmolecular.com/partnering/
- 19 Oct 2022 Early research in Pain in USA (Parenteral) ((Integral Molecular pipeline, October 2022))